To identify the biomarkers for determining sensitivity of HCC to this novel agent, we treated 13 HCC cell lines with NZ001, selective MET tyrosine kinase inhibitor PF-04217903 and another putative MET and VEGFR2 tyrosine kinase inhibitor XL-184 in an in vitro antiproliferation screen. The gene discussed is MET; the disease is hepatocellular carcinoma.